![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Degron and Takeda will collaborate to utilize Degron's GlueXplorer® platform to identify, validate, and optimize molecular glue degraders for specific therapeutic targets selected by Takeda.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $1,200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 23, 2024